Related references
Note: Only part of the references are listed.New prognostic markers in chronic lymphocytic leukemia
Carol Moreno et al.
BLOOD REVIEWS (2008)
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication
Francesc Bosch et al.
CLINICAL CANCER RESEARCH (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
Michael R. Grever et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine
E. Van Den Neste et al.
LEUKEMIA (2007)
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
Tadeusz Robak et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
A. R. Pettitt et al.
LEUKEMIA (2006)
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)
Tadeusz Robak et al.
BLOOD (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)
D Caballero et al.
CLINICAL CANCER RESEARCH (2005)
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV
M Valgañón et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway
A Klöpfer et al.
ONCOGENE (2004)
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia
PD Thornton et al.
HEMATOLOGY JOURNAL (2004)
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211
JC Byrd et al.
LEUKEMIA (2003)
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
PD Thornton et al.
ANNALS OF HEMATOLOGY (2003)
Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia
K Lin et al.
BLOOD (2002)
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy
S Stilgenbauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
KR Rai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
